Concepedia

Julie Holden

JH

Statistics

Publications

2

Citations

56

H-Index

2

Active since

2022

Affiliations

AstraZeneca (Finland)(Current)

AstraZeneca (Sweden)

AstraZeneca (Netherlands)

AstraZeneca (Poland)

AstraZeneca (United States)

Julie Holden is an author at AstraZeneca (Finland) specializing in systemic inflammation markers, endothelial dysfunction, and left ventricular diastolic dysfunction.

Publications per year

2022–2023

2

Publications

2

Rationale and Design of ENDEAVOR: A Sequential Phase 2b–3 Randomized Clinical Trial to Evaluate the Effect of Myeloperoxidase Inhibition on Symptoms and Exercise Capacity in Heart Failure with Preserved or Mildly Reduced Ejection Fraction

Lars H. Lund, Carolyn S.P. Lam, Patricia Ely Pizzato et al. · European Journal of Heart Failure · 2023 · 44 citations · Full text

, , +17

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial

Iain Squire, Anders Gabrielsen, Peter J. Greasley et al. · Clinical and Translational Science · 2022 · 12 citations · Full text

, , +17

1–2 of 2